IVF Hartmann Holding stock
VBSN.SWSIXIVF Hartmann Holding AG, HealthcareISIN CH0187624256
69Score 69 out of 100, Neutral
Price and trend
50 / 100
Price history
−8.6% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 6.5% below it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 31).
The price is 18% below its 52-week high. Largest decline in 20 years: 54% (March 2017 to September 2022).
Chart figures for advanced users
- SMA 50$151.52
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$158.51
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)31
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$145.20
- The lowest closing price of the last twelve months.
- Resistance$180.75
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- IVF Hartmann Holding AG belongs to the Medical (Specialties) industry (Switzerland) and, with a market value of $352.96M, is number 14 of 14 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $194.81M (up 1.8% year on year) and earnings of $22.04M (down 9.9%).
- MEQIRI Score 69 out of 100 (Neutral): rank 163 of 714 in Healthcare, median 53.
Show more
- The P/E is 14.4 (Healthcare sector median 26.7, own median of recent years 26.2).
- Our model puts fair value at $334.36, with the price 55% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 32.6% in fiscal 2025, Medical (Specialties) median 4.7%.Profitability 73
- Below fair valuePrice 55% below the fair value of $334.36.Valuation 77
- More cash than debtCash $130.41M, financial debt $5.37M.Stability 94
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and stability, while momentum and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 68 to 69.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
- calm price action
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $257.20 and expensive above $477.66 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $393.87 (cash-flow model) and $274.85 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 5.6%. At 6.6% the fair value would be $299.67, at 4.6% it would be $386.54.
Valuation metrics
Half from the cash-flow model, half from earnings times the sector P/E (26.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 6.9% on the twelve months before. Revenue has stayed largely stable since 2005.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 33%, operating 11%, net 11%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- No date announced.
- Last reported
- 31 Dec 2025EPS reported $5.05
Sector comparison
714 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Specialties)
The next larger companies by market value
- Medacta GroupMOVE.SW $2.64B58
- Eckert & ZieglerEUZ.DE $969.93M74
- QuidelOrthoQDEL $817.18M32
- Mesa LaboratoriesMLAB $782.43M58
- Shoulder InnovationsSI $458.61M48
- Mobia MedicalMOBI $448.43M45
- BrainsWayBWAY $440.87M60
- 908 DevicesMASS $415.82M43
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.